This product is a pyrimidine anti-metabolite drug that mainly acts on cells in the S proliferation phase. It interferes with cell proliferation by inhibiting the synthesis of cell DNA. After entering the human body, cytarabine is phosphorylated by kinase and converted into cytarabine triphosphate and cytarabine diphosphate. The former can strongly inhibit the synthesis of DNA polymerase, and the latter can inhibit the conversion of cytidine diphosphate to deoxycytidine diphosphate, thereby inhibiting cell DNA polymerization and synthesis. This product is a cell cycle-specific drug, which is most sensitive to cells in the S proliferation phase, and has a weaker effect on inhibiting RNA and protein synthesis.

This product is a pyrimidine anti-metabolite drug that mainly acts on cells in the S proliferation phase. It interferes with cell proliferation by inhibiting the synthesis of cell DNA. After entering the human body, cytarabine is phosphorylated by kinase and converted into cytarabine triphosphate and cytarabine diphosphate. The former can strongly inhibit the synthesis of DNA polymerase, and the latter can inhibit the conversion of cytidine diphosphate to deoxycytidine diphosphate, thereby inhibiting cell DNA polymerization and synthesis. This product is a cell cycle-specific drug, which is most sensitive to cells in the S proliferation phase, and has a weaker effect on inhibiting RNA and protein synthesis.

This product has an inhibitory effect on α-glycosidase, thereby inhibiting the hydrolysis of disaccharides and delaying the absorption of sugars. The concentration that inhibits 50% of the activity of α-glycosidase (maltase, sucrase) in the small intestine of pigs and rats is 10-8~10-9mol/L, which is 20~30 times that of the similar drug acarbose. This product competitively inhibits maltase, isomaltase and sucrase, and the inhibition constant is 1.5×10-9~7.0×10-9mol/L. It inhibits the increase in blood sugar after the intake of disaccharides (sucrose maltose) and starch, and has no effect on the increase in blood sugar after the intake of monosaccharides (glucose and fructose). It can reduce hypertriglyceridemia and hyperinsulinemia, and inhibit the onset of hyperglycemia. It improves insulin secretion disorders and glucose tolerance, and reduces urine sugar. It is almost not absorbed. Continuous administration can increase the weight of disaccharide hydrolases and small intestinal mucosa in the small intestinal mucosa, but it is a reversible change.

This product is a broad-spectrum quinolone antibacterial drug, which inhibits bacterial DNA gyrase and hinders bacterial DNA replication to achieve bacteriostatic and bactericidal effects. It has strong antibacterial activity against Gram-positive bacteria, Gram-negative bacteria, anaerobic bacteria, etc.

In vivo, it competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. Its main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, thereby playing a role in the prevention and treatment of atherosclerosis and coronary heart disease. It also reduces serum triglyceride levels and increases blood high-density lipoprotein levels.